Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New disc implant could replace neck fusion surgery

NCT ID NCT04469231

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new artificial disc, the Synergy Disc, to standard spinal fusion surgery for people with one-level cervical degenerative disc disease that hasn't improved with other treatments. About 175 adults aged 18-70 with neck and arm pain or nerve symptoms are being followed for at least 2 years. The goal is to see if the disc is as safe and effective as fusion, with less pain and better movement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Synergy Disc (artificial disc replacement device)
What this could lead to
If successful, this could offer a motion-preserving alternative to spinal fusion for patients with cervical disc disease, potentially reducing long-term complications.
What could go wrong
This is a non-randomized, historically controlled trial with 175 participants, so results may be less reliable than a randomized study. The device could fail or cause complications requiring additional surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

175 people

The number who actually took part.

Started

Oct 2020

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 70 years; 2. Diagnosis of radiculopathy or myelopathy of the cervical spine, with either radiculopathy symptoms - pain, paresthesia, or paralysis in a specific nerve root distribution C4, C5, C6, or C7, including at least one of the following: arm/shoulder pain (at least 30 mm on 100 mm VAS scale); decreased muscle strength of at least one level on the 0-5 scale described below; abnormal sensation, including hyperesthesia or hypoesthesia; and/or abnormal reflexes; or myelopathy symptoms including positive Romberg evaluation, abnormal heel/toe walk, pathologic hyperreflexia or clonus in lower extremity, positive Babinski, or positive Hoffman's; 3. Symptomatic at only one level from C3-C4 to C6-C7; 4. Radiographically determined pathology at level to be treated correlating to primary symptoms, including at least one of the following: 1. Decreased disc height compared to adjacent levels on radiographic film, CT, or MRI 2. Degenerative spondylosis on CT or MRI 3. Disc herniation on CT or MRI. 5. Neck Disability Index (NDI) score ≥ 30/100; 6. Unresponsive to non-operative treatment for six weeks, or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment; 7. Appropriate for treatment using an anterior surgical approach, including having no more than one previous anterior surgical approach to the cervical spine; 8. Ability and willingness to comply with follow-up regimen; and 9. Written informed consent given by subject or subject's legally authorized representative. Exclusion Criteria: 1. Infection at the site of surgery; 2. History of, or anticipated treatment for, active systemic infection, including HIV infection or hepatitis C; 3. Prior attempted or completed cervical spine surgery, except (1) laminoforaminotomy (greater than 6 months prior to scheduled surgical treatment), which includes removal of disc material necessary to perform a nerve root decompression, with less than one-third facetectomy at any level, or (2) a successful single-level anterior cervical fusion (greater than 6 months prior to scheduled surgical treatment); 4. More than one immobile vertebral level between C1-T1 from any cause, including but not limited to congenital abnormalities, osteoarthritic "spontaneous" fusions, and prior cervical spinal fusions; 5. Previous trauma to the C3-T1 levels resulting in significant bony or disco-ligamentous cervical spine injury; 6. Axial neck pain in the absence of other symptoms of radiculopathy or myelopathy justifying the need for surgical intervention; 7. Radiographic confirmation of severe facet joint disease or degeneration. 8. Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation) for females or MORES (Male Osteoporosis Risk Estimation Score), will be used to screen patients to determine those patients who require a Hip DXA, a bone mineral density measurement. A SCORE or MORES ≥ 6 requires a DXA. If DXA is required, exclusion will be defined as a DXA bone density measured T score ≤ -2.5 (The World Health Organization definition of osteoporosis). DXA scans within the last 6 months prior to surgical treatment may be used; 9. Paget's disease, osteomalacia, or any other metabolic bone disease (excluding osteoporosis which is addressed above); 10. Severe diabetes mellitus requiring daily insulin management; 11. Active malignancy: a history of any invasive malignancy (except non-melanoma skin cancer), unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years; 12. Tumor as source of symptoms; 13. Symptomatic DDD or significant cervical spondylosis at two or more levels; 14. Marked cervical instability on resting lateral or flexion/extension radiographs demonstrated by: 1. Translation \> 3.5 mm and/or 2. 11° angular difference to that of either adjacent level; 15. Known or suspected allergy to cobalt, chromium, molybdenum, titanium, or polyethylene; 16. Severe myelopathy to the extent that the patient is wheelchair bound; 17. Congenital canal stenosis resulting in a canal diameter of \< 10 mm, as measured by CT or MRI; 18. Kyphotic segmental angulation of greater than 11 degrees at treatment or adjacent levels; 19. Arachnoiditis; 20. Pregnant (verified in patients of childbearing potential by a negative urine pregnancy test when pre-admission testing is obtained), or interested in becoming pregnant during the duration of the study; 21. Autoimmune disorders that impact the musculoskeletal system (e.g., lupus, rheumatoid arthritis; ankylosing spondylitis); 22. Congenital bony and/or spinal cord abnormalities that affect spinal stability; 23. Spinal axis disease (thoracic or lumbar) to the extent that surgical consideration is likely anticipated within 6 months after the cervical procedure; 24. Other degenerative joint disease (e.g. shoulder, hip, knee) to the extent that surgical consideration is likely anticipated within 6 months after the cervical procedure; 25. Diseases or conditions that would preclude accurate clinical evaluation (e.g. neuromuscular disorders such as diffuse idiopathic skeletal hyperostosis (DISH)); 26. Medications that could interfere with fusion or other bone/soft tissue healing (e.g. anticipated continued use of systemic steroid medication postoperatively); 27. Currently experiencing acute episode of major mental illness (psychosis, major affective disorder, or schizophrenia), or manifesting physical symptoms without a diagnosable medical condition to account for the symptoms, which may indicate symptoms of psychological rather than physical origin; 28. Current or recent history of substance abuse (drug or alcohol) per site PI's determination; 29. Morbid obesity, defined as body mass index ("BMI") \> 40; 30. Currently using, or planning to use, bone growth stimulators in the cervical spine; 31. Use of any other investigational drug or medical device within the last 30 days prior to surgery; 32. Currently a prisoner; 33. Currently pursuing personal litigation (defined as litigation that will likely influence the patient's ability or willingness to accurately report their treatment outcomes) related to the neck or cervical spine injury; however, involvement in worker's compensation related litigation is not a required exclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical degenerative disc disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Anschutz Medical Center

    Aurora, Colorado, 80045, United States

  • Atlantic Brain & Spine

    Reston, Virginia, 20190, United States

  • Austin Neurosurgeons

    Austin, Texas, 78746, United States

  • Barrow Brain and Spine

    Phoenix, Arizona, 85013, United States

  • Center for Sports Medicine and Orthopaedic Surgery (CSMO)

    Chattanooga, Tennessee, 37404, United States

  • Central Texas Brain & Spine

    Austin, Texas, 78705, United States

  • Exiamia EquiHealth

    Durham, North Carolina, 27704, United States

  • HonorHealth Research Institute/Barrow Brain and Spine

    Scottsdale, Arizona, 85251, United States

  • Hospital for Special Surgery

    New York, New York, 10021, United States

  • Indiana Spine Group

    Carmel, Indiana, 46032, United States

  • Institute of Neuro Innovation

    Santa Monica, California, 90404, United States

  • Kennedy White Orthopaedic Center

    Sarasota, Florida, 34232, United States

  • Michigan Orthopedic Surgeons

    Southfield, Michigan, 48033, United States

  • Michigan Orthopedic Surgeons (2)

    Southfield, Michigan, 48033, United States

  • Orthopedic Specialty Institute

    Orange, California, 92868, United States

  • Summit Spine

    Portland, Oregon, 97225, United States

  • Texas Spine Care Center

    San Antonio, Texas, 78231, United States

  • The Disc Replacement Center

    West Jordan, Utah, 84088, United States

  • Todd H. Lanman, M.D.

    Beverly Hills, California, 90210, United States

  • Upstate Medical University

    East Syracuse, New York, 13057, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.